MCID: LKM002
MIFTS: 65

Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Leukemia

Summaries for Leukemia

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. There are different types of leukemia, including Acute lymphocytic leukemia Acute myeloid leukemia Chronic lymphocytic leukemia Chronic myeloid leukemia Leukemia can develop quickly or slowly. Chronic leukemia grows slowly. In acute leukemia, the cells are very abnormal and their number increases rapidly. Adults can get either type; children with leukemia most often have an acute type. Some leukemias can often be cured. Other types are hard to cure, but you can often control them. Treatments may include chemotherapy, radiation and stem cell transplantation. Even if symptoms disappear, you might need therapy to prevent a relapse. NIH: National Cancer Institute

MalaCards based summary : Leukemia, also known as leukemias, is related to myeloid leukemia and acute leukemia, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Leukemia is MIR27A (MicroRNA 27a), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Decitabine and Azacitidine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone marrow, and related phenotypes are Increased HDAC inhibitor resistance and cellular

Disease Ontology : 12 A cancer that affects the blood or bone marrow characterized by an abnormal proliferation of blood cells.

Wikipedia : 73 Leukemia, also spelled leukaemia, is a group of blood cancers that usually begin in the bone marrow and... more...

Related Diseases for Leukemia

Diseases in the Leukemia family:

Chronic Leukemia Acute Leukemia
Subacute Leukemia

Diseases related to Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2809)
# Related Disease Score Top Affiliating Genes
1 myeloid leukemia 33.9 RUNX1 RAF1 NPM1 MLF1 LIF FLT3
2 acute leukemia 33.7 RUNX1 PBX1 NPM1 FLT3 ETV6 BCR
3 leukemia, chronic myeloid 33.7 RUNX1 RAF1 PML HOTAIR FLT3 ETV6
4 childhood acute lymphocytic leukemia 33.5 RUNX1 PBX1 FLT3 ETV6 BCR ABL1
5 childhood leukemia 33.5 RUNX1 PBX1 ETV6 BCR ABL1
6 t-cell acute lymphoblastic leukemia 33.4 RUNX1 FLT3 ETV6 ABL1
7 acute megakaryocytic leukemia 33.4 RUNX1 NPM1 FLT3 ETV6
8 juvenile myelomonocytic leukemia 33.4 RUNX1 RAF1 FLT3 ETV6
9 chronic myelomonocytic leukemia 33.3 RUNX1 NPM1 FLT3 ETV6
10 mixed phenotype acute leukemia 33.3 RUNX1 FLT3 ABL1
11 leukemia, acute lymphoblastic 33.3 TCL1A RUNX1 PML PBX1 MIR27A FLT3
12 b-lymphoblastic leukemia/lymphoma 33.3 PBX1 FLT3 ETV6 BCR ABL1
13 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 33.2 RUNX1 FLT3 ETV6
14 atypical chronic myeloid leukemia 33.2 RUNX1 FLT3 ETV6 ABL1
15 precursor t-cell acute lymphoblastic leukemia 33.1 TCL1A FLT3 ETV6 BCR ABL1
16 myelodysplastic syndrome 33.1 RUNX1 NPM1 MLF1 FLT3 ETV6 ABL1
17 adult acute lymphocytic leukemia 33.1 PBX1 ETV6 ABL1
18 leukemia, chronic lymphocytic 33.1 TCL1A NEAT1 MIR27A FLT3 BCR ABL1
19 acute myeloblastic leukemia with maturation 33.1 NPM1 FLT3
20 chronic eosinophilic leukemia 33.1 FLT3 ETV6 ABL1
21 chronic leukemia 33.0 FLT3 BCR ABL1
22 leukemia, acute lymphoblastic 3 33.0 RUNX1 PBX1 FLT3 ETV6 BCR ABL1
23 acute myeloblastic leukemia without maturation 33.0 NPM1 FLT3
24 cytogenetically normal acute myeloid leukemia 33.0 NPM1 FLT3
25 b-cell adult acute lymphocytic leukemia 32.9 PBX1 BCR ABL1
26 core binding factor acute myeloid leukemia 32.9 RUNX1 FLT3
27 myeloproliferative neoplasm 32.8 RUNX1 FLT3 ETV6 BCR ABL1
28 b-lymphoblastic leukemia/lymphoma with hypodiploidy 32.8 PBX1 ETV6 ABL1
29 myelodysplastic/myeloproliferative neoplasm 32.7 FLT3 ETV6 ABL1
30 b-lymphoblastic leukemia/lymphoma with iamp21 32.7 PBX1 ETV6 ABL1
31 acute promyelocytic leukemia 32.7 RUNX1 PML NPM1 NEAT1 HOTAIRM1 FLT3
32 cebpa-associated familial acute myeloid leukemia 32.6 RUNX1 NPM1 FLT3 ETV6
33 etv6 thrombocytopenia and predisposition to leukemia 32.4 RUNX1 NPM1 FLT3 ETV6
34 8p11 myeloproliferative syndrome 32.4 RUNX1 FLT3 BCR
35 testicular leukemia 32.3 ETV6 ABL1
36 philadelphia-negative chronic myeloid leukemia 32.2 BCR ABL1
37 acute myeloid leukemia with t(8;21)(q22;q22) translocation 32.0 RUNX1 FLT3
38 leukemia, acute myeloid 32.0 RUNX1 PML PBX1 NPM1 MLF1 MIR331
39 myelofibrosis 31.6 RUNX1 NPM1 FLT3 ETV6 CDKN2B-AS1
40 b-cell lymphoma 31.4 TCL1A NPM1 HOTAIR GAS5 BCR
41 lymphoma, non-hodgkin, familial 31.4 TCL1A NPM1 MIR331 MIR27A FLT3 ETV6
42 hematologic cancer 31.1 RUNX1 NPM1 MIR331 MIR27A FLT3 ETV6
43 myeloma, multiple 31.0 MIR331 MIR27A HOTAIR GAS5 FLT3
44 gastrointestinal stromal tumor 30.8 RAF1 HOTAIR FLT3 ABL1
45 pediatric lymphoma 30.5 TCL1A NPM1
46 bone marrow cancer 30.5 NPM1 MIR27A FLT3 ETV6 ABL1
47 retinitis pigmentosa 11 30.2 NEAT1 HOTAIR ETV6
48 thyroid carcinoma 29.8 NEAT1 MLF1 HOTAIR GAS5 CDKN2B-AS1
49 osteogenic sarcoma 29.7 NEAT1 HOTAIR GAS5 CDKN2B-AS1
50 glioma 29.5 NEAT1 HOTAIR GAS5 CDKN2B-AS1

Comorbidity relations with Leukemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Leukemia, Chronic Lymphocytic

Graphical network of the top 20 diseases related to Leukemia:



Diseases related to Leukemia

Symptoms & Phenotypes for Leukemia

UMLS symptoms related to Leukemia:


angina pectoris; chest pain; edema

GenomeRNAi Phenotypes related to Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased HDAC inhibitor resistance GR00115-A-0 8.62 LIF LIFR

MGI Mouse Phenotypes related to Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ABL1 BCR ETV6 FLT3 LIF MLF1
2 hematopoietic system MP:0005397 10.03 ABL1 BCR ETV6 FLT3 LIF LIFR
3 endocrine/exocrine gland MP:0005379 10.02 ABL1 ETV6 FLT3 LIF LIFR MLF1
4 immune system MP:0005387 9.93 ABL1 BCR ETV6 FLT3 LIF LIFR
5 liver/biliary system MP:0005370 9.61 ABL1 BCR ETV6 LIF LIFR NPM1
6 neoplasm MP:0002006 9.1 ETV6 FLT3 NPM1 PML RAF1 RUNX1

Drugs & Therapeutics for Leukemia

Drugs for Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 795)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
2
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Cladribine Approved, Investigational Phase 4 4291-63-8 20279
7
Daunorubicin Approved Phase 4 20830-81-3 30323
8
Teniposide Approved Phase 4 29767-20-2 34698
9
ofatumumab Approved Phase 4 679818-59-8 6918251
10
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
11
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
12
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
14
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
15
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
16
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
19
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
20
Thioguanine Approved Phase 4 154-42-7 2723601
21
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
22
Cefepime Approved, Investigational Phase 4 88040-23-7 5479537
23
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
24
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
25
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
26
Nitric Oxide Approved Phase 4 10102-43-9 145068
27
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
28
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
29
Busulfan Approved, Investigational Phase 4 55-98-1 2478
30
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
31
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
32
Prilocaine Approved Phase 4 721-50-6 4906
33
Rasburicase Approved, Investigational Phase 4 134774-45-1
34
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
35
Venetoclax Approved, Investigational Phase 4 1257044-40-8 49846579
36
Chlorambucil Approved Phase 4 305-03-3 2708
37
tannic acid Approved Phase 4 1401-55-4
38
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
39
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
40
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
41
Zidovudine Approved Phase 4 30516-87-1 35370
42
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
43
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
44
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
45
Daclizumab Investigational, Withdrawn Phase 4 152923-56-3
46
Uric acid Investigational Phase 4 69-93-2 1175
47
Ethylene Phase 4 74-85-1 6325
48 Serotonin 5-HT3 Receptor Antagonists Phase 4
49 Methylprednisolone Acetate Phase 4
50 Cyclooxygenase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 6344)
# Name Status NCT ID Phase Drugs
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
2 Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants Unknown status NCT01339988 Phase 4 Busulfan/Cyclophosphamide
3 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
4 Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
6 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
7 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
8 A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
9 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
10 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
11 Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study Unknown status NCT02926586 Phase 4 Fludarabine;Cytarabine
12 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
13 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
14 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
15 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
16 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
17 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Unknown status NCT03216070 Phase 4 Dasatinib 50 MG
18 Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia. Unknown status NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
19 A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
20 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
21 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
22 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
23 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
25 AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) Unknown status NCT00180128 Phase 4 all-trans retinoid acid;idarubicin;mitoxantrone;daunorubicin;cytarabine
26 Treatment of Relapsed Acute Promyelocytic Leukemia With Arsenic Trioxide (Phase IV Study) Unknown status NCT00196768 Phase 4 Arsenic trioxide;Trisenox
27 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
28 Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Unknown status NCT02784561 Phase 4 Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG(Sanofi/Genzyme)
29 Treatment of Elderly Patients (>60 Years) With Acute Myeloblastic Leukemia or Advanced MDS (RAEB-T): An Open Randomized Study to Test the Efficacy of G-CSF-Priming and a Feasibility Trial of Dose-Reduced Allogeneic Transplantation and of Autologous Stem Cell Transplantation Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
30 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
31 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
32 A Multi-center, Open-label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
33 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
34 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
35 PETHEMA LAM07: Prospective, Multicenter, Uncontrolled Cohort Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
36 A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
37 FLAT: Fludarabine, Cytarabine and Topotecan in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
38 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
39 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
40 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
41 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Completed NCT02447718 Phase 4
42 An Open-label, Multicenter Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
43 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
44 FLAG-IDA Chemotherapy Induction Follow by Intensive Chemotherapy Postremission +/- Autologous Hemopoietic Stem Cell Transplantation or Bone Marrow Transplantation in Patients With High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia. Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
45 A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib Completed NCT01043874 Phase 4 Nilotinib
46 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
47 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
48 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
49 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
50 An Open-label, Multicenter Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to ENACT (CAMN107A2109) Trial Completed NCT01368523 Phase 4 nilotinib

Search NIH Clinical Center for Leukemia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Isotretinoin
Methotrexate
Methotrexate Sodium
Pipobroman
Vincristine
Vincristine Sulfate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia

Genetic Tests for Leukemia

Genetic tests related to Leukemia:

# Genetic test Affiliating Genes
1 Leukemia 29

Anatomical Context for Leukemia

MalaCards organs/tissues related to Leukemia:

40
Myeloid, T Cells, Bone Marrow, Bone, B Cells, Nk Cells, Breast

Publications for Leukemia

Articles related to Leukemia:

(show top 50) (show all 50226)
# Title Authors PMID Year
1
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions. 61 42
33397387 2021
2
Diagnosis of a Rare Form of Leukemia at a Glance Thanks to Pathognomonic Skin Lesions. 42 61
33559594 2020
3
Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. 42
33479542 2021
4
Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. 47
21070600 2011
5
Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins. 54 61
20362031 2010
6
Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. 61 54
20435628 2010
7
Expression pattern of the septin gene family in acute myeloid leukemias with and without MLL-SEPT fusion genes. 61 54
19748670 2010
8
Nup98-homeodomain fusions interact with endogenous Nup98 during interphase and localize to kinetochores and chromosome arms during mitosis. 54 61
20237156 2010
9
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. 61 54
19701750 2010
10
Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. 61 54
20237505 2010
11
Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. 54 61
20237320 2010
12
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia. 61 54
20223922 2010
13
Genetic variation in the folate metabolic pathway and risk of childhood leukemia. 61 54
20101025 2010
14
Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. 54 61
20236310 2010
15
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. 54 61
20124512 2010
16
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. 54 61
20332322 2010
17
Identification of Zfp521/ZNF521 as a cooperative gene for E2A-HLF to develop acute B-lineage leukemia. 61 54
20062079 2010
18
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. 61 54
20072157 2010
19
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). 61 54
20170098 2010
20
Analysis of Ikaros family splicing variants in human hematopoietic lineages. 54 61
20432734 2010
21
The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. 54 61
20038611 2010
22
Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways. 61 54
20231472 2010
23
MEIS proteins as partners of the TLX1/HOX11 oncoprotein. 54 61
19559479 2010
24
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. 61 54
20026798 2010
25
The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. 54 61
20093438 2010
26
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. 61 54
20008304 2010
27
Malignant transformation of Slp65-deficient pre-B cells involves disruption of the Arf-Mdm2-p53 tumor suppressor pathway. 54 61
20008789 2010
28
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. 61 54
20008787 2010
29
Impact of breast cancer resistance protein on cancer treatment outcomes. 61 54
19949928 2010
30
Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell lines. 54 61
20084277 2010
31
Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2. 61 54
20237898 2010
32
Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias. 61 54
19919827 2010
33
A prototype nonpeptidyl, hydrazone class, thrombopoietin receptor agonist, SB-559457, is toxic to primary human myeloid leukemia cells. 54 61
19880492 2010
34
Up-regulation of survivin by the E2A-HLF chimera is indispensable for the survival of t(17;19)-positive leukemia cells. 61 54
19887369 2010
35
Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. 54 61
19801969 2010
36
[Expression of c-fes gene in leukemia cells and its clinical significance]. 54 61
20030920 2009
37
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. 61 54
20032408 2009
38
The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. 61 54
19773546 2009
39
Effects of Manisa propolis on telomerase activity in leukemia cells obtained from the bone marrow of leukemia patients. 61 54
19817639 2009
40
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis. 54 61
19907659 2009
41
TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia. 54 61
19786618 2009
42
E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease. 61 54
19734451 2009
43
High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia. 61 54
19643984 2009
44
New structural arrangement of the extracellular regions of the phosphate transporter SLC20A1, the receptor for gibbon ape leukemia virus. 54 61
19717569 2009
45
Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. 54 61
19666867 2009
46
Transformation from committed progenitor to leukemia stem cells. 54 61
19796242 2009
47
Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant. 61 54
19682090 2009
48
HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. 54 61
19291801 2009
49
On the mechanism of multiple lysine methylation by the human mixed lineage leukemia protein-1 (MLL1) core complex. 61 54
19556245 2009
50
STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells. 54 61
19709433 2009

Variations for Leukemia

Copy number variations for Leukemia from CNVD:

7 (show all 44)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 19383 1 150034000 245120000 Amplification Leukemia
2 33637 1 46800000 50700000 Loss Leukemia
3 44329 10 55250865 57057708 Rearrangement PCDH15 Leukemia
4 62297 12 10760000 26234000 Amplification Leukemia
5 64439 12 12800000 14800000 Gain SLC2A14 Leukemia
6 64440 12 12800000 14800000 Gain SLC2A3 Leukemia
7 69764 12 56263000 69037000 Amplification Leukemia
8 69765 12 56263000 69037000 Amplification Leukemia
9 74441 13 107000000 115169878 Loss Leukemia
10 77064 13 39703000 40042000 Amplification Leukemia
11 86548 14 62100000 64800000 Gain SYNE2 Leukemia
12 109053 17 24000000 81195210 Copy number SLC2A1 Leukemia
13 112810 17 41159000 78182000 Amplification Leukemia
14 127115 19 26500000 59128983 Gain Leukemia
15 134399 2 10062000 11645000 Amplification Leukemia
16 138038 2 15720000 16465000 Amplification Leukemia
17 138662 2 16873000 60356000 Amplification Leukemia
18 138663 2 16873000 60356000 Amplification Leukemia
19 147406 2 64333000 65547000 Amplification Leukemia
20 153044 20 33909000 62377000 Amplification Leukemia
21 156917 20 9002000 17491000 Amplification Leukemia
22 159831 21 45112000 46015000 Amplification Leukemia
23 161203 22 17722000 17723000 Amplification Leukemia
24 165015 22 41000000 44200000 Gain RRP7A Leukemia
25 165016 22 41000000 44200000 Gain SERHL Leukemia
26 172851 3 18696000 18818000 Amplification Leukemia
27 173075 3 189413414 190080135 Translate LPP Leukemia
28 191719 6 1 60500000 Loss of mismatch HLA-A Leukemia
29 191720 6 1 60500000 Loss of mismatch HLA-B Leukemia
30 191721 6 1 60500000 Loss of mismatch HLA-C Leukemia
31 200024 5 48400000 180915260 Deletion Leukemia
32 204999 6 118500000 171115067 Gain Leukemia
33 205139 6 121263000 130387000 Deletion Leukemia
34 206061 6 135502452 135540311 Gain MYB Leukemia
35 215006 6 70000000 114600000 Loss Leukemia
36 226598 7 59900000 159138663 Deletion Leukemia
37 246206 9 117700000 122500000 Loss Leukemia
38 250022 9 19900000 25600000 Deletion CDKN2A Leukemia
39 250028 9 19900000 25600000 Loss CDKN2A Leukemia
40 250692 9 21957750 21984490 Deletion CDKN2A Leukemia
41 253950 9 49000000 141213431 Deletion Leukemia
42 254016 9 50700000 114900000 Loss Leukemia
43 304060 5 23543480 23564463 Mutation PRDM9 Leukemia
44 304367 7 1780332 38257086 Deletion DOCK4 Leukemia

Expression for Leukemia

Search GEO for disease gene expression data for Leukemia.

Pathways for Leukemia

Pathways related to Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.36 RUNX1 RAF1 PML FLT3 BCR ABL1
2 12.11 RAF1 MIR331 MIR27A ABL1
3 11.73 NPM1 FLT3 BCR ABL1
4 11.38 RUNX1 PML PBX1 MLF1 FLT3 ETV6
5 11.08 RUNX1 RAF1 PML FLT3

GO Terms for Leukemia

Biological processes related to Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.87 RUNX1 RAF1 PBX1 NPM1 LIF ETV6
2 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.61 TCL1A RAF1 LIF
3 hematopoietic stem cell proliferation GO:0071425 9.46 RUNX1 ETV6
4 leukemia inhibitory factor signaling pathway GO:0048861 9.4 LIFR LIF
5 regulation of cytokine-mediated signaling pathway GO:0001959 9.37 RUNX1 LIFR
6 regulation of cell differentiation GO:0045595 9.33 RUNX1 RAF1 LIF
7 myeloid progenitor cell differentiation GO:0002318 9.26 MLF1 FLT3
8 thymus development GO:0048538 9.13 RAF1 PBX1 ABL1
9 positive regulation of cell proliferation GO:0008284 9.1 TCL1A PBX1 NPM1 LIFR LIF FLT3

Sources for Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap